does semaglutide work as well as tirzepatide vs Semaglutide & Tirzepatide: Can You

Priyadarsini et al., 2025)

A comprehensive review of clinical trials from 2021 highlights that once-weekly subcutaneous semaglutide (1 mg) consistently lowered HbAc by 1.5 to 1.8% over 30 to 56 weeks, outperforming other medications including sitagliptin, dulaglutide, and insulin glargine in the SUSTAIN series.33 Real-world data from 2023 further support these findings, showing an average HbA1c reduction of approximately 0.9% and a fasting blood glucose decrease of 26 mg/dL after six months of once-weekly semaglutide use.34 These results underscore semaglutides ability to offer meaningful improvements in glycemic control and metabolic health for patients with T2DM

the latter explanation is suggested by our results (see Fig

Hashem et al

It's always recommended to consult with a healthcare professional if you notice any significant side effects

A., Al-Harbi, M